CN116077631A - 涉及粘液素的疾病治疗 - Google Patents

涉及粘液素的疾病治疗 Download PDF

Info

Publication number
CN116077631A
CN116077631A CN202211366234.9A CN202211366234A CN116077631A CN 116077631 A CN116077631 A CN 116077631A CN 202211366234 A CN202211366234 A CN 202211366234A CN 116077631 A CN116077631 A CN 116077631A
Authority
CN
China
Prior art keywords
composition
cancer
mucin
pharmaceutically acceptable
prodrug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202211366234.9A
Other languages
English (en)
Chinese (zh)
Inventor
D.L.莫里斯
罗杰.阿斯顿
贾韦德.阿赫塔尔
克里希那.皮莱
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NewSouth Innovations Pty Ltd
Original Assignee
NewSouth Innovations Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2012905519A external-priority patent/AU2012905519A0/en
Application filed by NewSouth Innovations Pty Ltd filed Critical NewSouth Innovations Pty Ltd
Publication of CN116077631A publication Critical patent/CN116077631A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C12Y304/22032—Stem bromelain (3.4.22.32)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C12Y304/22033—Fruit bromelain (3.4.22.33), i.e. juice bromelain

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
CN202211366234.9A 2012-12-17 2013-12-17 涉及粘液素的疾病治疗 Pending CN116077631A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AU2012905519 2012-12-17
AU2012905519A AU2012905519A0 (en) 2012-12-17 Treatment of diseases involving mucin
CN201380070938.4A CN104968358B (zh) 2012-12-17 2013-12-17 涉及粘液素的疾病治疗
PCT/AU2013/001474 WO2014094041A1 (en) 2012-12-17 2013-12-17 Treatment of diseases involving mucin

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201380070938.4A Division CN104968358B (zh) 2012-12-17 2013-12-17 涉及粘液素的疾病治疗

Publications (1)

Publication Number Publication Date
CN116077631A true CN116077631A (zh) 2023-05-09

Family

ID=50977393

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202211366234.9A Pending CN116077631A (zh) 2012-12-17 2013-12-17 涉及粘液素的疾病治疗
CN201380070938.4A Active CN104968358B (zh) 2012-12-17 2013-12-17 涉及粘液素的疾病治疗

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201380070938.4A Active CN104968358B (zh) 2012-12-17 2013-12-17 涉及粘液素的疾病治疗

Country Status (13)

Country Link
US (2) US11369666B2 (enExample)
EP (1) EP2931296B1 (enExample)
JP (1) JP6502853B2 (enExample)
KR (1) KR102255753B1 (enExample)
CN (2) CN116077631A (enExample)
AU (3) AU2013362878B2 (enExample)
CA (1) CA2895149C (enExample)
DK (1) DK2931296T3 (enExample)
ES (1) ES2727686T3 (enExample)
NZ (1) NZ631536A (enExample)
TR (1) TR201907858T4 (enExample)
WO (1) WO2014094041A1 (enExample)
ZA (1) ZA201503979B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1255815A1 (zh) 2015-07-16 2019-08-30 Prospect CharterCare RWMC, LLC d/b/a Roger Williams Medical Center 治疗腹膜癌的组合物和方法
US11364286B2 (en) 2015-10-14 2022-06-21 Newsouth Innovations Pty Limited Compositions and methods for the treatment of diseases involving mucin
JPWO2017195792A1 (ja) * 2016-05-13 2019-03-14 国立大学法人 熊本大学 新規なｐｅｇ修飾酵素及びそれを用いた抗がん剤デリバリー
CN108066413A (zh) * 2016-11-15 2018-05-25 李雁 标准桃金娘油的癌性黏液溶解作用及抗肿瘤新用途
MY210170A (en) * 2018-02-23 2025-08-30 MUCPharm Pty Ltd Formulations containing mucin-affecting proteases
JP7645192B2 (ja) 2019-03-07 2025-03-13 ノボ メディシン インク． カスパーゼ阻害剤及びその使用方法
EP3797783A1 (en) 2019-09-27 2021-03-31 Freie Universität Berlin Novel medical uses of thiol-functionalized polyglycerol derivatives
WO2021217221A1 (en) * 2020-05-01 2021-11-04 MUCPharm Pty Ltd Preventing and treating viral infections
JP2024539275A (ja) * 2021-10-27 2024-10-28 エムユーシーファーム ピーティーワイ リミテッド 呼吸器疾患を治療するための方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH695414A5 (de) * 2001-05-30 2006-05-15 Guenter Holzner Kosmetische Präparate gegen die Alterung der menschlichen Haut in einer Mehrkammer-Mischpackung.
US20070166362A1 (en) * 2004-10-07 2007-07-19 Shuji Sakuma Transdermal and transmucosal preparations
US20080075710A1 (en) * 2006-09-25 2008-03-27 Liquid Potions Llc Herbal composition for treating hangovers
CN103285383A (zh) * 2013-06-03 2013-09-11 海南通用同盟药业有限公司 一种包含菠萝蛋白酶的药物组合物及菠萝蛋白酶肠溶片

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
DE4302060A1 (de) * 1993-01-26 1994-07-28 Mucos Pharma Gmbh & Co Verwendung von Bromelain zur Krebstherapie und/oder Metastasen-Prophylaxe
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
JPH08337532A (ja) * 1995-06-14 1996-12-24 Takeda Chem Ind Ltd 医薬組成物
AT408615B (de) 1998-09-15 2002-01-25 Immuno Ag Neue influenzavirus-impfstoffzusammensetzung
GB9923176D0 (en) 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
US6517832B1 (en) * 2001-08-24 2003-02-11 Jeffrey L. Marrongelle Formulations and methods for treating chronic migraine
DK1694137T3 (da) * 2003-11-26 2009-04-27 Hills Pet Nutrition Inc Fremgangsm de til at reducere lugt af aff ring fra k ledyr
AR054822A1 (es) 2005-07-07 2007-07-18 Sanofi Pasteur Emulsion inmuno adyuvante
US20100166726A1 (en) * 2007-03-07 2010-07-01 Northeastern University Compositions for improving cellular uptake of a chemotherapeutic agent in a cell exhibiting mucin deregulation
TWI461193B (zh) * 2009-07-24 2014-11-21 Taipei Veterans General Hospital 水飛薊或水飛薊賓用於治療神經受損之用途
JP5614978B2 (ja) * 2009-12-22 2014-10-29 独立行政法人農業・食品産業技術総合研究機構 穀物由来のプロアントシアニジン含有抽出物、及びその製造方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH695414A5 (de) * 2001-05-30 2006-05-15 Guenter Holzner Kosmetische Präparate gegen die Alterung der menschlichen Haut in einer Mehrkammer-Mischpackung.
US20070166362A1 (en) * 2004-10-07 2007-07-19 Shuji Sakuma Transdermal and transmucosal preparations
US20080075710A1 (en) * 2006-09-25 2008-03-27 Liquid Potions Llc Herbal composition for treating hangovers
CN103285383A (zh) * 2013-06-03 2013-09-11 海南通用同盟药业有限公司 一种包含菠萝蛋白酶的药物组合物及菠萝蛋白酶肠溶片

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
吴梧桐: "《酶类药物学》", 31 January 2011, 中国医药科技出版社, pages: 456 *
郑芙林等: "《实用临床医学全书》", 31 March 1998, 合肥：安徽科学技术出版社, pages: 1335 - 1337 *

Also Published As

Publication number Publication date
HK1211213A1 (en) 2016-05-20
AU2017204436A1 (en) 2017-07-20
KR20150096445A (ko) 2015-08-24
AU2019203315A1 (en) 2019-05-30
AU2013362878A1 (en) 2015-06-18
ES2727686T3 (es) 2019-10-17
DK2931296T3 (da) 2019-06-03
CN104968358A (zh) 2015-10-07
AU2017204436B2 (en) 2019-05-30
NZ631536A (en) 2016-12-23
EP2931296A4 (en) 2016-08-10
CN104968358B (zh) 2022-11-18
TR201907858T4 (tr) 2019-06-21
EP2931296B1 (en) 2019-02-27
WO2014094041A1 (en) 2014-06-26
US11369666B2 (en) 2022-06-28
JP6502853B2 (ja) 2019-04-17
ZA201503979B (en) 2017-11-29
US20150343035A1 (en) 2015-12-03
CA2895149A1 (en) 2014-06-26
CA2895149C (en) 2023-08-22
US20220401529A1 (en) 2022-12-22
EP2931296A1 (en) 2015-10-21
JP2016502981A (ja) 2016-02-01
KR102255753B1 (ko) 2021-05-26
AU2013362878B2 (en) 2017-03-30

Similar Documents

Publication Publication Date Title
US20220401529A1 (en) Treatment of diseases involving mucin
JP2007535525A (ja) β−カルボリン誘導体を含有する医薬組成物および癌を処置するためのそれらの使用
JP2005538093A (ja) 抗血管形成療法のための、テトラポリアンモニウムテトラチオモリブデートおよび関連化合物
WO1999048503A1 (en) Antitumor composition containing a synergistic combination of an anthracycline derivative with a camptothecin derivate
EP3062790A1 (en) Pharmaceutical combinations for the treatment of cancer
TW201609094A (zh) 治療癌症之新穎方法
EP1968981B1 (en) Azaxanthones and use thereof for treating tumors
AU2016340017B2 (en) Compositions and methods for the treatment of diseases involving mucin
US20080293648A1 (en) Compositions and Methods for Cancer Treatment
HK1211213B (en) Treatment of diseases involving mucin
WO2025232723A1 (en) Treatment method with focal adhesion kinase inhibitor
CN104619325A (zh) 治疗肿瘤的组合药物及其应用
HK1116186B (en) Azaxanthones and use thereof for treating tumors
HK1229695A1 (en) Novel methods for treating cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20230509